INTRODUCTION
Current risk-group classification in pediatric acute myeloid leukemia (AML) is determined by recurrent cytogenetic aberrations together with early treatment response. 1 However, the majority of patients are stratified in the intermediate risk group, including patients with cytogenetically normal AML (CN-AML), representing 20-25% of all children with AML. Molecular markers with prognostic implications have been identified in pediatric AML, such as internal tandem duplications of the FTL3 gene (FLT3/ITD), and mutations in NPM1 and the Wilms tumor 1 (WT1) gene, which may further refine risk-group classification. [2] [3] [4] Mutations in CEBPA, encoding the CCAAT/enhancer binding protein alpha (C/EBP!), have also been detected in AML. 5, 6 C/EBP! is one of the crucial transcription factors for myeloid cell development. Targeted disruption of the CEBPA gene results in a selective early block of granulocyte differentiation. 7, 8 C/EBP! function is frequently abrogated in AML by mutations, but also by (post)transcriptional or posttranslational inhibition due to dysregulation by oncogenes such as AML1-ETO, CBF-MYH11 and FLT3-ITD. [9] [10] [11] [12] [13] More recently, epigenetic modification through hypermethylation of the CEBPA promoter, resulting in CEBPA silencing, has also been reported. 14, 15 Various mutations throughout CEBPA have been described, but two locations are most frequently affected. [16] [17] [18] N-terminal frame shift mutations are located between the major translational start site and a second ATG further downstream. They result in truncation of the full-length p42 isoform of C/EBP!, while preserving the shorter p30 isoform, which has been shown to inhibit the function of full-length p42. 9 C-terminal mutations are in-frame insertions or deletions located in the basic leucine zipper (bZIP) domain, and impair DNA binding and/or homo-and heterodimerization. 19 The majority of AML patients with CEBPA mutations harbor a mutation at both locations (CEBPA double-mutants), and these are typically on different alleles, resulting in the lack of wild-type C/EBP! p42 expression in these cases. 20, 21 However, also single CEBPA mutations occur, in which expression of the wild-type product is retained, however, at lower levels.
CEBPA mutations are found in 5-14% of adult AML cases, and are associated with a favorable outcome in adult AML. 5, 6, [21] [22] [23] [24] In contrast, CEBPA promoter hypermethylation has been suggested to confer a poor outcome. 15 Pediatric data are available from 2 studies, showing CEBPA mutations in 4.5 and 6% of cases, and only the Children's Oncology Group (COG) reported outcome data according to CEBPA status, which confirmed association with a favorable outcome. 25, 26 Recently, 2 adult studies found that the favorable prognosis was uniquely associated with CEBPA double-mutant AML, but not with the presence of a CEBPA single mutation. 27, 28 In the COG study however, CEBPA single-mutant AML showed a favorable outcome comparable to double-mutant AML. Pediatric data on CEBPA promoter hypermethylation are lacking to date.
Interestingly, adult studies showed a highly characteristic gene expression signature for CEBPA doublemutant AML, in contrast with single-mutant AML. 27 Of interest, CEBPA promoter hypermethylated cases showed a similar signature as the CEBPA double-mutants, which is apparently characterized by the lack of C/EBP! functioning. 15 In this study we investigated the characteristics, expression profiles and impact of CEBPA mutations and promoter hypermethylation in a large series of pediatric AML. We showed the independent favorable outcome of patients with CEBPA double-mutant AML. Five CEBPA-silenced cases were identified by combining screening for promoter hypermethylation and gene expression profiling, of which 4 cases relapsed. Furthermore, we showed, for the first time in pediatric AML, that gene expression profiles of CEPBA double-mutant and silenced cases cluster, pointing towards a common hallmark of abrogated C/EBP! function in these AMLs.
DESIGN AND METHODS

Study cohort
Viably frozen bone marrow (BM) or peripheral blood (PB) samples taken at initial diagnosis from 252 children with AML were provided based on availability by the Dutch Childhood Oncology Group (DCOG; The Hague, the Netherlands), the AML-'Berlin-Frankfurt-Münster' Study Group (AML-BFM-SG; Hannover, Germany, and Prague, Czech Republic) and the Hôpital Saint-Louis (Paris, France). In addition, 33 paired initial diagnosisrelapse BM or PB samples, and 7 paired initial diagnosis-remission BM samples were provided by the DCOG and AML-BFM-SG. Institutional review board approval for these studies has been obtained according to local laws and regulations. Each study group performed central review of the morphological, immunophenotypical and cytogenetic classification, and provided data on the clinical follow-up.
After thawing, leukemic cells were isolated from these samples as previously described. 29 Blast percentages were >80% as assessed morphologically on May-Grünwald-Giemsa-stained cytospin slides.
Genomic DNA and total cellular RNA were extracted using TRIzol reagent (Invitrogen, Breda, the Netherlands), as described before.
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Survival analysis was restricted to de novo AML patients treated according to DCOG and AML-BFM-SG studies (i.e. DCOG/AML-BFM 87, DCOG 92/94, DCOG 97, AML-BFM 98 and 04) to reduce treatment variability, and because this comprised the majority of patients (n=185). Hence, patients treated according to other protocols (n=43), and, in addition, patients with PML-RAR! (n=15) or with secondary AML (n=8) were excluded. Details of the treatment protocols and overall outcome data have been previously published, with the exception of study AML-BFM 04, which has been recently closed. In these protocols, treatment consisted of 4 to 5 blocks of intensive chemotherapy, using a standard cytarabine and anthracycline backbone. Stem cell transplantation (SCT) in first complete remission (CR1) was used only in selected high-risk patients. There was no statistically significant difference between the treatment protocols for obtaining CR (p=0.65) nor in event-free survival (p=0.41), but for overall survival there was a difference between the protocols (p=0.04). However, patients with CEBPA single-mutated AML, double-mutated AML and wild-type AML were equally distributed over the different treatment protocols (p=0.28).
Cytogenetic and molecular analysis
Samples were routinely screened for cytogenetic aberrations using standard chromosome-banding-karyotyping, and further analyzed for recurrent non-random genetic aberrations characteristic for AML, including t(15;17), inv (16), t(8;21) and MLL-gene rearrangements, using RT-PCR and/or fluorescent in-situ hybridization (FISH) by each study group. In case of lacking data, RT-PCR or FISH was performed at the laboratory of Pediatric
Oncology of the Erasmus MC-Sophia Children's Hospital.
Hotspot regions for mutations of c- KIT, FLT3, MLL, NPM1, PTPN11, were screened for, as previously described. 2 Regions of NOTCH1 known to be mutated in T-ALL (heterodimerization domain (HD), exons 26 and 27; proline-glutamate-serine-threonine-rich domain (PEST), exon 34) were also analyzed for the presence of mutations with a (nested) PCR-based direct sequencing approach.
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Analysis of CEBPA mutations and promoter hypermethylation
Mutation analysis of CEBPA was performed as previously described 21 , with minor modifications. Primer sequences and PCR conditions are described in Table S1 . Genomic DNA was PCR amplified using specific primers, i.e. primers 1 and 10, and 4 and 8, to cover the whole CEBPA gene. Purified PCR products were directly sequenced from both strands using the described primers on an ABI Prism 3100 genetic analyzer (Applied Biosystems, Foster City, CA USA). The sequence data were analyzed using CLC Workbench version 3.5.1 (CLC Bio, Aarhus, Denmark).
For methylation analysis of the promoter region of CEBPA, genomic DNA was treated with sodium bisulfite using the EZ DNA Methylation kit (Zymo Research, Orange, CA USA) according to the manufacturer's protocol. The bisulfite-treated DNA was used as a template for methylation-specific PCR (MSP) and unmethylation-specific PCR (USP), which were performed as previously described. 14 MSP and USP products were subsequently separated by gel electrophoresis and visualized with ethidium-bromide.
Gene expression profiling and analysis
Integrity of total RNA was checked using the Agilent 2100 Bio-analyzer (Agilent, Santa Clara, CA USA).
Biotinylated cRNA was synthesized, hybridized and processed on the Affymetrix Human Genome U133 Plus 2.0 Array (Affymetrix, Santa Clara, CA USA) according to the manufacturer's guidelines. Unsupervised clustering analysis was performed and visualized as previously described. 32 Briefly, probe set intensity values were normalized using MAS5.0 software and values <30 were set on 30. For each probe set the geometric mean of the intensity values of all samples was calculated. The level of expression of each probe set in every sample was then determined relative to this geometric mean and logarithmically transformed (on a base 2 scale). The transformed expression data were subsequently imported into OmniViz software, (OmniViz v3.7, Tewksbury, MA USA) . Pairwise correlations between the gene expression profiles of the 237 samples was calculated with
Pearson's correlation on the basis of 1608 differently expressed probe sets representing the subset of probe sets with a factor 16 increase or decrease relative to the geometric mean.
To test the probe set prediction signatures previously described in adult AML for our pediatric CEBPA silenced cases and CEBPA single-and double-mutant cases, normalized probe set intensities for the 237 cases were used in a linear prediction algorithm (linear discriminant analysis; equal prior probabilities, predicting 4
variables: Partek v6.09.1008, Missouri, USA), with both the described 21 and 9-probe sets. 15, 27 Prediction result of samples were visualized using PCA scatterplot (Partek), and both cases and probe sets were hierarchically clustered using Euclidean distance (Genemaths XT, Applied Maths, Austin, TX USA).
Other statistical analyses
Statistical analyses were performed with SPSS 15.0 (SPSS Inc. Chicago, ILL USA). Variables were compared using the " 2 or Fisher exact test for categorical values, the Mann-Whitney-U test for continuous values, and the Kruskal-Wallis test when more than 2 groups were compared.
To assess outcome, the following parameters were used: complete remission (CR, defined as less than 5% blasts in the bone marrow, with regeneration of trilineage hematopoiesis plus absence of leukemic cells in the cerebrospinal fluid or elsewhere), probability of event-free survival (pEFS, defined as time between diagnosis and first event, including failure to achieve remission, relapse, death by any cause or second malignancy) and probability of overall survival (pOS, defined as time between diagnosis and death). pEFS and pOS were estimated by the Kaplan-Meier method, and compared using the log-rank test. The independency of prognostic factors was examined by multivariate Cox regression analysis. All tests were two-tailed and p-values <0.05 were considered statistically significant.
RESULTS
Single and double CEBPA mutations in pediatric AML
We identified 34 CEBPA mutations in 20 out of 252 (7.9%) diagnostic patient samples by sequencing the entire coding region ( Figure 1A , Table S2 ). Of these, 13 cases had the combination of an N-terminal frame shift mutation and an in-frame mutation in the bZIP region. One case combined an N-terminal frame shift mutation with a frame shift-causing insertion before the bZIP region. These 14 cases (70%) are further referred to as CEBPA double mutants. The other 6 cases carried a single CEBPA mutation; i.e. 4 in-frame bZIP mutations and 2 frame shift mutations in the TAD2 domain and before the bZIP domain, respectively. The latter two cases do not represent the classical N-terminal mutation, as also the C/EBP! p30 isoform will be affected, but because of their functional consequence they were classified as mutations.
Cases with an in-frame insertion polymorphism(s) in TAD2 20, 33 showed that the presence of a CEBPA double mutation was an independent favorable prognostic factor for pOS (HR 0.23; p=0.04) as well as pEFS (HR 0.32; p=0.03) ( Table 2) . CEBPA single mutations were not included in the multivariate analysis as a factor because of the small number of cases.
Aberrant CEBPA promoter hypermethylation in pediatric AML
Methylation-specific PCR could be performed in 237 cases and revealed hypermethylation of the CEBPA promoter region in 3 cases only (1.3%) ( Figure 1B ). As expected, CEBPA gene expression (determined with probe set 204039_at, and depicted in Figure 3 ) was down-regulated in these cases. Characteristics of these 3
CEBPA-hypermethylated cases are shown in Table 3 . CEBPA promoter hypermethylation was also present in the relapse material of these latter 2 patients, demonstrating clonal stability of the hypermethylation pattern.
Unsupervised analysis reveals clustering of CEBPA mutant and hypermethylated cases
Unsupervised cluster analysis of 237 de novo pediatric AML cases showed distinctive clusters ( Figure 3A ).
Cases with CEBPA mutations and promoter hypermethylation predominantly clustered together, referred to as the main CEBPA cluster. This cluster contained 15 cases in total, including 8 double-mutants and all 3 hypermethylated cases. Of interest, 2 CEBPA single-mutant AMLs were also present in this main CEBPA cluster, despite the fact that these cases are expected to have wild-type expression of C/EBP! p42, in contrast to CEBPA double-mutant and hypermethylated cases. Interestingly, extremely high TRIB2 expression (probe set 202478_at) was present in 1 of these CEBPA single-mutant cases (#5041), which may explain C/EBP! p42-inhibition of its remaining allele, as TRIB2 directly inactivates C/EBP! p42.
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Furthermore, the two remaining cases in the CEBPA main cluster had low CEBPA gene expression, and clustered closely with the 3 CEBPA-hypermethylated AMLs, despite the fact that we did not detect hypermethylation in these cases using MSP ( Figure 3B , Table 3 ). Of note, one of these cases presented also with very high TRIB2 expression (#4728). So, taken together, 5 cases with silenced CEBPA were found in 237 de novo pediatric AMLs (2.1%). Four of these cases experienced a relapse, and only 1 patient was in continuous CR after a HSCT (Table 3) . Clearly, a common gene expression signature was shared for all the cases in the CEBPA main cluster, which was confirmed when comparing this cluster with all others ( Figure S1 , Table S4 ).
T-cell characteristics of CEBPA-silenced cases in pediatric AML
As CEBPA-silenced cases were reported to express T-cell lineage genes and NOTCH1 mutations in adults, we next investigated T-cell characteristics and screened for NOTCH1 mutations in our 5 silenced cases. 15 Flow cytometry data revealed high CD7 expression in all 5 cases besides myeloid (CD33/CD13 and CD11b) and stem-cell markers (CD34 and CD117) (Table S5) . One case weakly expressed cCD3 (#5033), but expression of other T-cell antigens was not seen. However, high mRNA expression of CD3 (CD3Z: 210031_at, CD3G:
206804_at and CD3D: 213539_at) was seen in all cases (Table S5) . Also high LCK expression, which is a wellknown T-lineage marker (probe set 204891_s_at) 35 , was found in all 5 cases. We did not detect NOTCH1 mutations in the HD-or PEST-domain in our 5 CEBPA-silenced cases.
Prediction of CEBPA double-mutant and -silenced cases using adult AML gene signatures
We utilized previously established gene prediction signatures in adult AML, based on 21 and 9 probe sets for CEBPA double-mutant and CEBPA-silenced cases respectively 15, 27 . Of the 12 CEBPA double-mutant cases, 10
were correctly predicted using the 21 probe sets-containing signature, 1 predicted as being a single mutant, and 1 as a silenced case (sensitivity 83%, specificity 99%) (Table S6A) . Visualizing these results, we see the double mutants forming a main cluster apart from the wild-types ( Figure S2A and B). However, also 3 CEBPA single-mutant cases (1 predicted as a double mutant), with the single mutation located in the bZIP region, clustered with the CEBPA double-mutant cases.
The 9 probe sets-signature for CEBPA-silenced cases predicted 3 of our 5 silenced cases, but also 1 CEBPA wild-type was false positively recognized (Table S6B , Figure S2C and D). This resulted in a low sensitivity (60%) of these probe sets for the prediction of CEBPA-silenced cases on our pediatric series.
DISCUSSION
In this study we investigated CEBPA aberrations in pediatric AML to determine their frequency and prognostic impact, but also to gain further insight in the heterogeneity and biology of pediatric AML. We detected CEBPA mutations in 7.9% of pediatric AML cases, which is comparable with the frequency reported in adult AML (5-14%) 9, [21] [22] [23] [24] , and with the two available pediatric series from Taiwan (6%) and North-America (4.5%).
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Seventy percent of CEBPA-mutated cases carried a double mutation, which is in agreement with previous studies reporting that the majority of CEBPA-mutated cases carried double mutations, typically affecting both alleles. 20, 21 Recently, two adult reports postulated that CEBPA single-and double-mutant AML are different entities, as favorable outcome was uniquely associated with CEBPA double mutants. 27, 28 Moreover, double mutants were characterized by a specific gene expression signature, in contrast with CEBPA single mutants. This is further sustained by recently published data obtained in mouse models that showed an efficient synergistic effect on leukemic transformation of the two different CEBPA mutations. [36] [37] [38] Single CEBPA mutations however are believed to predispose the pre-leukemic initiating cell to subsequent acquirement of secondary (epi)genetic mutations necessary before development of full-blown AML. [37] [38] Despite small numbers, we observed differences between CEBPA single-and double-mutant AML, both in presenting characteristics as well as in prognosis. Considering the presenting characteristics, CEBPA double-mutant AML did not occur in very young patients, was restricted to FAB M1/M2 subtypes, and had the highest association with CN-AML. However, compared with CEBPA double mutants, no higher frequency of additional molecular aberrations was detected in CEBPA single-mutant cases.
Considering prognosis, only CEBPA double-mutants were associated with a favorable outcome with a 5-year overall survival of 79%. Single mutants, had a relatively poor outcome in our series (5-year pOS 25%). In fact, CEBPA double-mutant cases had a comparable outcome as the favorable subgroup of CBF-AML. This is in agreement with the results of the pediatric COG-study 25 , which showed an outcome of approximately 80% overall survival at 5 years for CEBPA double-mutants. Multivariate analysis confirmed the independent prognostic significance of CEBPA double mutations, which points to its potential as marker for further refinement of risk-group stratification in pediatric AML, when validated in prospective series. The mechanism of the relative drug sensitivity of the CEBPA double-mutated cases remains to be elucidated. The outcome of single-mutant cases in the COG series (5-year pOS 85%) was similar to double-mutant cases. Despite the fact that the numbers of single-mutant cases in both series were small, we hypothesize this difference in outcome between our studies may be based on the underlying biology of the type of the single mutation (i.e. a mutation at the N-terminus, bZIP region or other location) as different leukemogenic capacities have been associated with the different mutation types 37 , or by different cooperating genetic events. Further studies after the single-mutant group in pediatric and adult AML are clearly warranted to determine the impact of the different mutation types and cooperating genetic aberrations.
Germ-line CEBPA mutations have been discovered in familial AML, in which the N-terminal mutation is present in the germ-line, and frequently a second CEBPA bZIP mutation was somatically acquired as a second hit to develop AML. 39, 40 The frequency of germ-line mutations in adult AML with CEBPA mutations was estimated at 11% (2 out of 18). 41 Here we showed a similar frequency: 1 out of 7 pediatric CEBPA-mutated cases carried a germ-line mutation. In our pediatric case we also found an N-terminal mutation in the germ-line, and a somatically acquired bZIP mutation. The occurrence of AML in both children and adults with germ-line CEBPA mutations illustrates a variable latency time.
Promoter hypermethylation of CEBPA was present at a low frequency in our pediatric series. These hypermethylated cases indeed showed CEBPA-silencing and, utilizing unsupervised clustering of gene expression data, these cases clustered together with the double-mutant cases. In addition, 2 other cases with CEBPA-silencing without promoter hypermethylation were detected, which clustered together with the hypermethylated cases. The mechanism of gene silencing in these 2 silenced cases still has to be elucidated, which might be hypermethylation in other regions of the promoter, 42 silencing by other epigenetic processes or by binding of miRNAs. All 5 CEBPA-silenced cases carried T-lymphoid characteristics beside their myeloid and stem cell markers. However, no NOTCH1 mutations were detected, which may be due to the small number as in the adult cases NOTCH1 mutations were present in only 50% 15 . In contrast with the favorable outcome of the CEBPA double-mutant cases, 4 out of the 5 CEBPA-silenced cases experienced a relapse. Interestingly, the patient not relapsing received a stem cell transplant. Cases with silenced CEBPA due to hypermethylation may potentially benefit from the use of demethylating agents.
Clustering of CEBPA-silenced and double-mutant cases points towards a common feature of C/EBP! inactivation of these leukemias. Cases in this CEBPA main cluster clearly shared a specific distinct gene expression profile. However, the main cluster can also be divided in two sub-clusters, separating the doublemutant and silenced cases, which may underlie biologic factors influencing drug resistance and therewith the difference in prognosis between the two subgroups. Differences in methylation profiles have indeed already been shown between these two subgroups. 43 Interestingly, 2 CEBPA single-mutants, which are expected to have fulllength C/EBP! p42 expression of the unaffected allele, also aggregated in this cluster. In 1 of these cases, high TRIB2 expression was detected, which is known to directly inactivate the C/EBP! p42 isoform 34. Complete C/EBP! p42 inactivation of the wild-type allele is hereby established and clustering with AML's without functional C/EBP! p42 can be explained. The mechanism of the expected C/EBP! p42 inactivation in the other single-mutant case remains to be elucidated.
We tried to predict CEBPA double-mutant and silenced cases in our pediatric series based on a prediction signature derived from adult studies. For CEBPA double-mutants, a high sensitivity and specificity was reached, although 1 single-mutant was also falsely predicted, and 2 single-mutants clustered with the double-mutant cases. These 3 cases however, carried a mutation in the bZIP region, which were shown previously to have a tendency towards a CEBPA double-mutant gene expression profile. 27 Prediction of the CEBPA-silenced cases was difficult due to a low sensitivity.
In conclusion, we showed the independent favorable outcome of patients with CEBPA double-mutant AML in a large pediatric AML series. Hence, CEBPA double-mutants may improve risk-group stratification in pediatric AML, when these data can be validated in prospective series. For the first time, CEBPA silenced cases are suggested to confer a poor outcome in pediatric AML, and this warrants further investigation of this CEBPA aberration. Furthermore, clustering of gene expression profiles provided insight in the biologic similarities and diversities of CEBPA aberrations in pediatric AML.
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